Checkpoint Therapeutics Inc.

2.84-0.1300-4.38%Vol 653.02K1Y Perf 85.39%
Apr 16th, 2021 16:00 DELAYED
BID2.83 ASK2.96
Open2.99 Previous Close2.97
Pre-Market- After-Market-
 - -  - -%
Target Price
17.67 
Analyst Rating
Strong Buy 1.00
Potential %
522.18 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap213.60M 
Earnings Rating
Neutral
Price Range Ratio 52W %
35.53 
Earnings Date
5th May 2021

Today's Price Range

2.813.00

52W Range

1.445.38

5 Year PE Ratio Range

-8.80-4.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-3.73%
1 Month
-17.44%
3 Months
-15.22%
6 Months
9.65%
1 Year
85.39%
3 Years
-29.88%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CKPT2.84-0.1300-4.38
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
ProfitabilityValueIndustryS&P 500US Markets
-
-2 044.60
-2 044.60
-1 366.40
-
RevenueValueIndustryS&P 500US Markets
97.00K
0.00
-13.71
-11.40
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.08-0.17-112.50
Q03 2020-0.08-0.09-12.50
Q02 2020-0.09-0.090.00
Q01 2020-0.16-0.0662.50
Q04 2019-0.17-0.22-29.41
Q03 2019-0.13-0.15-15.38
Q02 2019-0.12-0.15-25.00
Q01 2019-0.17-0.18-5.88
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.1363.89Positive
6/2021 QR-0.1355.17Positive
12/2021 FY-0.50--
12/2022 FY-0.55--
Next Report Date5th May 2021
Estimated EPS Next Report-0.13
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume653.02K
Shares Outstanding75.21M
Trades Count2.66K
Dollar Volume3.47M
Avg. Volume1.36M
Avg. Weekly Volume690.32K
Avg. Monthly Volume709.28K
Avg. Quarterly Volume1.43M

Checkpoint Therapeutics Inc. (NASDAQ: CKPT) stock closed at 2.84 per share at the end of the most recent trading day (a -4.38% change compared to the prior day closing price) with a volume of 655.83K shares and market capitalization of 213.60M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Checkpoint Therapeutics Inc. CEO is James F. Oliviero.

The one-year performance of Checkpoint Therapeutics Inc. stock is 85.39%, while year-to-date (YTD) performance is 7.17%. CKPT stock has a five-year performance of %. Its 52-week range is between 1.44 and 5.38, which gives CKPT stock a 52-week price range ratio of 35.53%

Checkpoint Therapeutics Inc. currently has a PE ratio of -7.30, a price-to-book (PB) ratio of 6.36, a price-to-sale (PS) ratio of 2 011.21, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -64.15%, a ROC of -102.68% and a ROE of -82.58%. The company’s profit margin is -%, its EBITDA margin is -2 044.60%, and its revenue ttm is $97.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Checkpoint Therapeutics Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Checkpoint Therapeutics Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Checkpoint Therapeutics Inc. is Strong Buy (1), with a target price of $17.67, which is +522.18% compared to the current price. The earnings rating for Checkpoint Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Checkpoint Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Checkpoint Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.50, ATR14 : 0.32, CCI20 : -91.10, Chaikin Money Flow : -0.02, MACD : -0.15, Money Flow Index : 33.72, ROC : -7.19, RSI : 43.54, STOCH (14,3) : 22.22, STOCH RSI : 0.37, UO : 50.94, Williams %R : -77.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Checkpoint Therapeutics Inc. in the last 12-months were: James F. Oliviero (Sold 118 790 shares of value $412 270 ), William Garrett Gray (Sold 62 934 shares of value $171 276 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

CEO: James F. Oliviero

Telephone: +1 781 652-4500

Address: 2 Gansevoort Street, New York 10014, NY, US

Number of employees: 8

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

73%27%

Bearish Bullish

53%47%

Bearish Bullish

56%44%

News

Stocktwits